BioHarvest Sciences Inc. Common Stock
BHSTConsumer DefensiveNASDAQPackaged Foods · Last scanned Sep 8, 2026
Scan Results
Daily timeframeBioHarvest Sciences Inc. Common Stock operates as a biotechnology company in Israel and the United States. Valued at $41.3M, BHST is a micro-cap name in its sector. It operates through two segments: Products and CDMO Services.
Market Cap
$41.3M
Beta
1.35
P/E (TTM)
—
P/E (Fwd)
-5.43
EPS (TTM)
$-0.51
EPS (Fwd)
$-0.34
ROE
-142.5%
ROA
-11.0%
Cash
$16.2M
Total Debt
$15.7M
Free CF
-$11.8M
52W Change
-75.0%
Annual Financials
Cash vs Debt
Where BHST stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BHST finished 46.63% below its 150-day moving average ($3.56) and 53.55% below its 200-day moving average ($4.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BHST overbought or oversold?
At the September 3, 2026 close, BHST's RSI(14) was 35.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $16.2M in cash comfortably exceeding the $15.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$11.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -142.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5.5M (2022) to $34.5M (2025), reflecting a 528% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioHarvest Sciences Inc. Common Stock and its sector.